Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9508 |
High Similarity |
NPD3027 |
Phase 3 |
0.8828 |
High Similarity |
NPD1613 |
Approved |
0.8828 |
High Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8718 |
High Similarity |
NPD228 |
Approved |
0.8583 |
High Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.8516 |
High Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.8125 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.8125 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.8047 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.8016 |
Intermediate Similarity |
NPD1357 |
Approved |
0.8015 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7972 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7969 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7852 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7852 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7846 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7823 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7795 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7794 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7755 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7705 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7692 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7692 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7687 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7676 |
Intermediate Similarity |
NPD2219 |
Phase 1 |
0.7669 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7635 |
Intermediate Similarity |
NPD37 |
Approved |
0.7623 |
Intermediate Similarity |
NPD290 |
Approved |
0.7616 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.76 |
Intermediate Similarity |
NPD7843 |
Approved |
0.7591 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7584 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7584 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7576 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7574 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7574 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7559 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7535 |
Intermediate Similarity |
NPD3060 |
Approved |
0.7518 |
Intermediate Similarity |
NPD2674 |
Phase 3 |
0.7518 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.75 |
Intermediate Similarity |
NPD3021 |
Approved |
0.75 |
Intermediate Similarity |
NPD940 |
Approved |
0.75 |
Intermediate Similarity |
NPD291 |
Approved |
0.75 |
Intermediate Similarity |
NPD3022 |
Approved |
0.75 |
Intermediate Similarity |
NPD846 |
Approved |
0.7484 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7484 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7484 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7483 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7483 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7483 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7483 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7483 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7481 |
Intermediate Similarity |
NPD9494 |
Approved |
0.7448 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7436 |
Intermediate Similarity |
NPD9296 |
Approved |
0.7432 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7431 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7429 |
Intermediate Similarity |
NPD6111 |
Discontinued |
0.7424 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7417 |
Intermediate Similarity |
NPD1242 |
Phase 1 |
0.7413 |
Intermediate Similarity |
NPD4237 |
Approved |
0.7413 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.7413 |
Intermediate Similarity |
NPD4236 |
Phase 3 |
0.7405 |
Intermediate Similarity |
NPD9381 |
Approved |
0.7405 |
Intermediate Similarity |
NPD9384 |
Approved |
0.7394 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7389 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7383 |
Intermediate Similarity |
NPD4675 |
Approved |
0.7383 |
Intermediate Similarity |
NPD4678 |
Approved |
0.7353 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7347 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7342 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7329 |
Intermediate Similarity |
NPD4357 |
Discontinued |
0.7324 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.732 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.7319 |
Intermediate Similarity |
NPD3144 |
Approved |
0.7319 |
Intermediate Similarity |
NPD3145 |
Approved |
0.7313 |
Intermediate Similarity |
NPD9622 |
Approved |
0.7308 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.7303 |
Intermediate Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.7296 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7296 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7292 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7278 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7273 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.7266 |
Intermediate Similarity |
NPD1726 |
Clinical (unspecified phase) |
0.7248 |
Intermediate Similarity |
NPD3687 |
Approved |
0.7248 |
Intermediate Similarity |
NPD3686 |
Approved |
0.7246 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7237 |
Intermediate Similarity |
NPD2977 |
Approved |
0.7237 |
Intermediate Similarity |
NPD2978 |
Approved |
0.7222 |
Intermediate Similarity |
NPD4750 |
Phase 3 |
0.7214 |
Intermediate Similarity |
NPD2238 |
Phase 2 |
0.72 |
Intermediate Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.7194 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7192 |
Intermediate Similarity |
NPD6190 |
Approved |
0.719 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7183 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7183 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7183 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7172 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7172 |
Intermediate Similarity |
NPD5177 |
Phase 3 |
0.7165 |
Intermediate Similarity |
NPD9280 |
Clinical (unspecified phase) |
0.7154 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7153 |
Intermediate Similarity |
NPD9619 |
Approved |
0.7153 |
Intermediate Similarity |
NPD9620 |
Approved |
0.7153 |
Intermediate Similarity |
NPD9621 |
Approved |
0.7152 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD7124 |
Phase 2 |
0.7132 |
Intermediate Similarity |
NPD8651 |
Approved |
0.712 |
Intermediate Similarity |
NPD968 |
Approved |
0.7113 |
Intermediate Similarity |
NPD6653 |
Approved |
0.7111 |
Intermediate Similarity |
NPD9269 |
Phase 2 |
0.7103 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7099 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7095 |
Intermediate Similarity |
NPD1774 |
Approved |
0.7092 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7075 |
Intermediate Similarity |
NPD2677 |
Approved |
0.7071 |
Intermediate Similarity |
NPD597 |
Approved |
0.7071 |
Intermediate Similarity |
NPD598 |
Approved |
0.7071 |
Intermediate Similarity |
NPD601 |
Approved |
0.707 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7063 |
Intermediate Similarity |
NPD1358 |
Approved |
0.7059 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7055 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7055 |
Intermediate Similarity |
NPD4162 |
Approved |
0.7055 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7054 |
Intermediate Similarity |
NPD821 |
Approved |
0.705 |
Intermediate Similarity |
NPD596 |
Approved |
0.705 |
Intermediate Similarity |
NPD600 |
Approved |
0.7047 |
Intermediate Similarity |
NPD4123 |
Phase 3 |
0.7047 |
Intermediate Similarity |
NPD3158 |
Phase 1 |
0.7047 |
Intermediate Similarity |
NPD3157 |
Approved |
0.7042 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7042 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7037 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7034 |
Intermediate Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.7025 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7021 |
Intermediate Similarity |
NPD1136 |
Approved |
0.7021 |
Intermediate Similarity |
NPD1130 |
Approved |
0.7021 |
Intermediate Similarity |
NPD1132 |
Approved |
0.7021 |
Intermediate Similarity |
NPD840 |
Approved |
0.7021 |
Intermediate Similarity |
NPD839 |
Approved |
0.7019 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7014 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.7014 |
Intermediate Similarity |
NPD5960 |
Phase 3 |
0.7014 |
Intermediate Similarity |
NPD5588 |
Approved |
0.7013 |
Intermediate Similarity |
NPD5773 |
Approved |
0.7013 |
Intermediate Similarity |
NPD5772 |
Approved |
0.7013 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7 |
Intermediate Similarity |
NPD52 |
Approved |
0.7 |
Intermediate Similarity |
NPD7527 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD3180 |
Approved |
0.7 |
Intermediate Similarity |
NPD7526 |
Approved |
0.7 |
Intermediate Similarity |
NPD3179 |
Approved |
0.6993 |
Remote Similarity |
NPD5089 |
Approved |
0.6993 |
Remote Similarity |
NPD5090 |
Approved |
0.6985 |
Remote Similarity |
NPD2235 |
Phase 2 |
0.6985 |
Remote Similarity |
NPD2231 |
Phase 2 |
0.698 |
Remote Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.6972 |
Remote Similarity |
NPD1240 |
Approved |
0.6972 |
Remote Similarity |
NPD3062 |
Approved |
0.6972 |
Remote Similarity |
NPD3059 |
Approved |
0.6972 |
Remote Similarity |
NPD3061 |
Approved |
0.6966 |
Remote Similarity |
NPD2161 |
Phase 2 |
0.6963 |
Remote Similarity |
NPD3496 |
Discontinued |
0.6959 |
Remote Similarity |
NPD5241 |
Discontinued |
0.6957 |
Remote Similarity |
NPD3094 |
Phase 2 |
0.6954 |
Remote Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.6953 |
Remote Similarity |
NPD556 |
Approved |
0.6929 |
Remote Similarity |
NPD5752 |
Clinical (unspecified phase) |
0.6923 |
Remote Similarity |
NPD3657 |
Discovery |
0.6923 |
Remote Similarity |
NPD5735 |
Approved |
0.6923 |
Remote Similarity |
NPD9377 |
Approved |
0.6923 |
Remote Similarity |
NPD447 |
Suspended |
0.6923 |
Remote Similarity |
NPD9379 |
Approved |
0.6923 |
Remote Similarity |
NPD9094 |
Approved |
0.6918 |
Remote Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.6918 |
Remote Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.6913 |
Remote Similarity |
NPD5058 |
Phase 3 |
0.6906 |
Remote Similarity |
NPD859 |
Approved |
0.6906 |
Remote Similarity |
NPD599 |
Approved |
0.6906 |
Remote Similarity |
NPD858 |
Approved |
0.6906 |
Remote Similarity |
NPD6584 |
Phase 3 |
0.6906 |
Remote Similarity |
NPD558 |
Phase 2 |
0.6906 |
Remote Similarity |
NPD602 |
Approved |
0.6903 |
Remote Similarity |
NPD6818 |
Clinical (unspecified phase) |
0.6901 |
Remote Similarity |
NPD6233 |
Phase 2 |
0.6894 |
Remote Similarity |
NPD7473 |
Discontinued |
0.6892 |
Remote Similarity |
NPD4110 |
Phase 3 |
0.6892 |
Remote Similarity |
NPD4628 |
Phase 3 |
0.6892 |
Remote Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.689 |
Remote Similarity |
NPD7240 |
Approved |
0.6889 |
Remote Similarity |
NPD5846 |
Approved |
0.6889 |
Remote Similarity |
NPD1778 |
Approved |
0.6889 |
Remote Similarity |
NPD6516 |
Phase 2 |
0.6889 |
Remote Similarity |
NPD4626 |
Approved |
0.6887
|
Remote Similarity |
NPD1940 |
Clinical (unspecified phase) |